Clinical pharmacology of sodium-glucose cotransporter-2 inhibitors

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A review of the clinical pharmacology of a new class of oral hypoglycemic drugs, sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors, or gliflozins), is presented. The main mechanism of action of SGLT-2, as well as other metabolic, cardiovascular, and renal effects, which are classified as pleiotropic class effects, is described. Data on the pharmacodynamics and pharmacokinetics of drugs (dapagliflozin, cancgliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, sotagliflozin), side effects and drug interactions are discussed. Data on the clinical pharmacology of the SGLT-2 class will contribute to a better understanding of the underlying mechanism of action and pleiotropic effects that provide cardioprotective and renoprotective effects.

全文:

受限制的访问

作者简介

Marina Leonova

Interregional Public Organization Association of Clinical Pharmacologists (Moscow Branch)

编辑信件的主要联系方式.
Email: anti23@mail.ru
ORCID iD: 0000-0001-8228-1114
SPIN 代码: 3281-7884

Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Natural Sciences

俄罗斯联邦, Moscow

参考

  1. Scheen A.J. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. doi: 10.1007/s40265-014-0337-y.
  2. Hsia D.S., Grove O., Cefalu W.T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diab Obes. 2017;24(1):73–9. doi: 10.1097/MED.0000000000000311.
  3. Kalra S., Shetty K.K., Nagarajan V.B., Ved J.K. Basic and clinical pharmacotherapeutics of SGLT2 inhibitors: a contemporary update. Diab Ther. 2020;11(4):813–33. doi: 10.1007/s13300-020-00789-y.
  4. Abdul-Ghani M.A., DeFronzo R.A., Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324–28. doi: 10.2337/db13-0604.
  5. Thomas M.C., Cherney D.Z.I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetol. 2018;61(10):2098–107. doi: 10.1007/s00125-018-4669-0.
  6. Patel D.K., Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diab Ther. 2019;10(5):1771–92. doi: 10.1007/s13300-019-00686-z.
  7. Monami M., Nardini C., Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diab Obes Metab. 2014;16(5):457–66. doi: 10.1111/dom.12244.
  8. Storgaard H., Gluud L.L., Bennett C., et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166125. doi: 10.1371/journal.pone.0166125.
  9. Zaccardi F., Webb D.R., Htike Z.Z., et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diab Obes Metab. 2016;18(8):783–94. doi: 10.1111/dom.12670.
  10. Mazidi M., Rezaie P., Gao H.K., Kengne A.P. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6):e004007. doi: 10.1161/JAHA.116.004007.
  11. Szekeres Z., Toth K., Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87. doi: 10.3390/metabo11020087.
  12. Yaribeygi H., Maleki M., Reiner Ћ., et al. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med. 2022;11(21):6544. doi: 10.3390/jcm11216544.
  13. Sanchez-Garcia A., Simental-Mendia M., Millan-Alanis J.M., Simental-Mendia L.E. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068. doi: 10.1016/j.phrs.2020.105068.
  14. Mukai J., Yoshiyama A., Kubota R. Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials. J Pharm Health Care Sci. 2020;6:4. doi: 10.1186/s40780-020-00160-0.
  15. Bechmann L.E., Emanuelsson F., Nordestgaard B.G., Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2023:117236. doi: 10.1016/j.atherosclerosis.2023.117236.
  16. Sano M., Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–87. doi: 10.1161/CIRCULATIONAHA.118.038881.
  17. Wang X., Fu R., Liu H., et al. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2021;10(6):6467–81. doi: 10.21037/apm-21-1022.
  18. Tian Q., Guo K., Deng J., et al. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. J Cell Mol Med. 2022;26(2):540–47. doi: 10.1111/jcmm.17115.
  19. Baker W.L., Smyth L.R., Riche D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75.e9. doi: 10.1016/j.jash.2014.01.007.
  20. Baker W.L., Buckley L.F., Kelly M.S., et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5):e005686. doi: 10.1161/JAHA.117.005686.
  21. Zhang Q., Zhou S., Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023;15(1):118. doi: 10.1186/s13098-023-01092-z.
  22. Reed J.W. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393–405. doi: 10.2147/VHRM.S111991.
  23. Zhang N., Wang Y., Tse G., et al. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(17):1961–73. doi: 10.1093/eurjpc/zwab173.
  24. Wang Y., Zhong Y., Zhang Z., et al. Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: A systematic review and meta-analysis. Front Endocrinol. (Lausanne). 2023;13:1088820. doi: 10.3389/fendo.2022.1088820.
  25. Fan G., Guo D.L. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials. Eur J Intern Med. 2023;114:49–57. doi: 10.1016/j.ejim.2023.04.002.
  26. Dhingra N.K., Mistry N., Puar P., et al. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC. Heart Fail. 2021;8(6):4693–700. doi: 10.1002/ehf2.13645.
  27. Zinman B., Wanner C., Lachin J.M., et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. doi: 10.1056/NEJMoa1504720.
  28. Neal B., Perkovic V., Mahaffey K.W., et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. doi: 10.1056/NEJMoa1611925.
  29. Wiviott S.D., Raz I., Bonaca M.P., et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57. doi: 10.1056/NEJMoa1812389.
  30. Cannon C.P., Pratley R., Dagogo-Jack S., et al.; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35. doi: 10.1056/NEJMoa2004967.
  31. Arnott C., Li Q., Kang A., et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908. doi: 10.1161/JAHA.119.014908.
  32. Bhattarai M., Salih M., Regmi M., et al. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA. Netw Open. 2022;5(1):e2142078. doi: 10.1001/jamanetworkopen.2021.42078.
  33. Gong C., Shen S.C., Zhang K., et al. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: a meta-analysis of randomized controlled clinical trials. Front Cardiovasc. Med. 2022;9:926979. doi: 10.3389/fcvm.2022.926979.
  34. Giugliano D., Longo M., Scappaticcio L., et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20(1):236. doi: 10.1186/s12933-021-01430-3.
  35. Teo Y.H., Teo Y.N., Syn N.L., et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):e019463. doi: 10.1161/JAHA.120.019463.
  36. Vaduganathan M., Docherty K.F., Claggett B.L., et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67. doi: 10.1016/S0140-6736(22)01429-5.
  37. DeFronzo R.A., Abdul-Ghani M. Sodium-glucose cotransporter 2 inhibitors and the kidney. Diab Spectr. 2021;34(3):225–34. doi: 10.2337/ds20-0071.
  38. Kim N.H., Kim N.H. Renoprotective Mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diab Metab J. 2022;46(4):543–51. doi: 10.4093/dmj.2022.0209.
  39. Salvatore T., Galiero R., Caturano A., et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651. doi: 10.3390/ijms23073651.
  40. Zelniker T.A., Wiviott S.D., Raz I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. doi: 10.1016/S0140-6736(18)32590-X.
  41. McGuire D.K., Shih W.J., Cosentino F., et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–58. doi: 10.1001/jamacardio.2020.4511.
  42. Neuen B.L., Young T., Heerspink H.J.L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet. Diab Endocrinol. 2019;7(11):845–54. doi: 10.1016/S2213-8587(19)30256-6.
  43. Perkovic V., Jardine M.J., Neal B., et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306. doi: 10.1056/NEJMoa1811744.
  44. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R., et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. doi: 10.1056/NEJMoa2024816.
  45. Wang C., Zhou Y., Kong Z., et al. The renoprotective effects of sodium–glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis. Diab Obes Metab. 2019;21:1018–26. doi: 10.1111/dom.13620.
  46. Bae J.H., Park E.G., Kim S., et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009. doi: 10.1038/s41598-019-49525-y.
  47. Bose D., Maurya M., Konwar M. Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: a meta-analysis of landmark renal and cardiovascular outcome trials. Indian J Pharmacol. 2023;55(2):119–27. doi: 10.4103/ijp.ijp_342_21.
  48. Bantounou M.A., Sardellis P., Thuemmler R., et al. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diab Obes Metab. 2024;26(2):710–20. doi: 10.1111/dom.15364.
  49. Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diab Ther. 2014;5(2):355–66. doi: 10.1007/s13300-014-0089-4.
  50. McGill J.B., Subramanian S. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am. J. Cardiol. 2019;124(Suppl. 1):S45–52. doi: 10.1016/j.amjcard.2019.10.029.
  51. Shi F.H., Li H., Shen L., et al. Appraisal of non-cardiovascular safety for sodium-glucose co-transporter 2 inhibitors: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Front Pharmacol. 2019;10:1066. doi: 10.3389/fphar.2019.01066.
  52. Liu J., Li L., Li S., et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. doi: 10.1038/s41598-017-02733-w.
  53. Bapir R., Bhatti K.H., Eliwa A., et al. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis. Arch Ital Urol Androl. 2023;95(2):11509. doi: 10.4081/aiua.2023.11509.
  54. Li D., Wang T., Shen S., et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diab Obes Metab. 2017;19(3):348–55. doi: 10.1111/dom.12825.
  55. Chen L., Xue Q., Yan C., et al. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Front Endocrinol. (Lausanne). 2023;14:1256548. doi: 10.3389/fendo.2023. 1256548.
  56. Donnan J.R., Grandy C.A., Chibrikov E., et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ. Open. 2019;9(1):e022577. doi: 10.1136/bmjopen-2018-022577.
  57. Scheen A.J. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295–304. doi: 10.1007/s40262-013-0128-8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024